B. Ljungberg, S. Campbell, H. Choi, D. Jacqmin, J. Lee et al., The Epidemiology of Renal Cell Carcinoma, European Urology, vol.60, issue.4, pp.615-636, 2011.
DOI : 10.1016/j.eururo.2011.06.049

J. Srigley, B. Delahunt, J. Eble, L. Egevad, J. Epstein et al., The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. The American journal of surgical pathology, pp.1469-89, 2013.

R. Motzer, T. Hutson, P. Tomczak, M. Michaelson, R. Bukowski et al., Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.115-139, 2007.
DOI : 10.1056/NEJMoa065044

L. Miller, S. Stemkowski, K. Saverno, D. Lane, Z. Tao et al., Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership, Journal of Managed Care & Specialty Pharmacy, vol.22, issue.3, pp.219-245, 2016.
DOI : 10.18553/jmcp.2016.22.3.219

S. Abdullah and R. Perez-soler, Mechanisms of resistance to vascular endothelial growth factor blockade, Cancer, vol.13, issue.pt 1, pp.3455-67, 2012.
DOI : 10.1158/1078-0432.CCR-07-1393
URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.26540/pdf

R. Thompson, H. Dong, and E. Kwon, Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy, Clinical Cancer Research, vol.13, issue.2, pp.709-724, 2007.
DOI : 10.1158/1078-0432.CCR-06-1868

R. Motzer, B. Escudier, D. Mcdermott, S. George, H. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015.
DOI : 10.1056/NEJMoa1510665

A. Baccos, E. Brunocilla, R. Schiavina, M. Borghesi, G. Rocca et al., Differing Risk of Cancer Death Among Patients With Pathologic T3a Renal Cell Carcinoma: Identification of Risk Categories According to Fat Infiltration and Renal Vein Thrombosis, Clinical Genitourinary Cancer, vol.11, issue.4, pp.451-458, 2013.
DOI : 10.1016/j.clgc.2013.05.006

J. Martinez-salamanca, W. Huang, I. Millan, R. Bertini, F. Bianco et al., Prognostic Impact of the 2009 UICC/AJCC TNM Staging System for Renal Cell Carcinoma with Venous Extension, European Urology, vol.59, issue.1, pp.120-127, 2011.
DOI : 10.1016/j.eururo.2010.10.001

E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 2009.
DOI : 10.1016/j.ejca.2008.10.026

S. Kammerer-jacquet, L. Crouzet, A. Brunot, J. Dagher, A. Pladys et al., clear cell renal cell carcinoma-A finding with therapeutic potential, International Journal of Cancer, vol.76, issue.1, 2016.
DOI : 10.1158/0008-5472.CAN-14-3362
URL : https://hal.archives-ouvertes.fr/hal-01439352

M. Bui, D. Seligson, K. Han, A. Pantuck, F. Dorey et al., Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy, Clin Cancer Res, vol.9, pp.802-813, 2003.

N. Rioux-leclercq, P. Fergelot, S. Zerrouki, E. Leray, F. Jouan et al., Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases, Human Pathology, vol.38, issue.10, pp.1489-95, 2007.
DOI : 10.1016/j.humpath.2007.02.014

N. Rioux-leclercq, P. Karakiewicz, Q. Trinh, V. Ficarra, L. Cindolo et al., Prognostic ability of simplified nuclear grading of renal cell carcinoma, Cancer, vol.127, issue.5, pp.868-74, 2007.
DOI : 10.1002/cncr.22463

S. Shin, Y. Jeon, P. Kim, Y. Cho, J. Koh et al., Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status, Annals of Surgical Oncology, vol.74, issue.Suppl 2, 2015.
DOI : 10.1158/0008-5472.CAN-13-0992

J. Jeuken, S. Cornelissen, M. Vriezen, M. Dekkers, A. Errami et al., MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas, Laboratory Investigation, vol.349, issue.10, pp.1055-65, 2007.
DOI : 10.1038/labinvest.3700664

N. Letang, L. Cabaniols, D. Pouessel, M. Robert, F. Iborra et al., Prognostic factors in renal cell carcinoma], Bull Cancer, vol.96, pp.475-84, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00375329

M. Yao, M. Yoshida, T. Kishida, N. Nakaigawa, M. Baba et al., VHL Tumor Suppressor Gene Alterations Associated With Good Prognosis in Sporadic Clear-Cell Renal Carcinoma, CancerSpectrum Knowledge Environment, vol.94, issue.20, pp.1569-75, 2002.
DOI : 10.1093/jnci/94.20.1569
URL : http://jnci.oxfordjournals.org/content/94/20/1569.full.pdf

Y. Vano, E. Tartour, L. Fournier, B. Beuselinck, A. Mejean et al., Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents, Expert Review of Anticancer Therapy, vol.194, issue.1, pp.523-565, 2014.
DOI : 10.1002/cncr.25219

R. Motzer, B. Escudier, R. Bukowski, B. Rini, T. Hutson et al., Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma, British Journal of Cancer, vol.108, issue.12
DOI : 10.1093/jjco/hyq146

G. Banumathy and P. Cairns, Signaling pathways in renal cell carcinoma, Cancer Biology & Therapy, vol.7, issue.7, pp.658-64, 2010.
DOI : 10.1200/JCO.2008.20.0766

B. Beuselinck, S. Job, E. Becht, A. Karadimou, V. Verkarre et al., Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting, Clinical Cancer Research, vol.21, issue.6, 2015.
DOI : 10.1158/1078-0432.CCR-14-1128

B. Beuselinck, A. Karadimou, D. Lambrechts, B. Claes, P. Wolter et al., Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib, British Journal of Cancer, vol.108, issue.4, pp.887-900, 2013.
DOI : 10.1200/JCO.2010.32.9110
URL : https://hal.archives-ouvertes.fr/hal-01064635

D. Heng, W. Xie, M. Regan, M. Warren, A. Golshayan et al., Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor???Targeted Agents: Results From a Large, Multicenter Study, Journal of Clinical Oncology, vol.27, issue.34, pp.5794-5803, 2009.
DOI : 10.1200/JCO.2008.21.4809

S. Ladoire, F. Bonnetain, M. Gauthier, S. Zanetta, J. Petit et al., Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents, The Oncologist, vol.16, issue.1, pp.71-81, 2011.
DOI : 10.1634/theoncologist.2010-0227

K. Nieman, I. Romero, B. Van-houten, and E. Lengyel, Adipose tissue and adipocytes support tumorigenesis and metastasis, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol.1831, issue.10, pp.1533-1574, 2013.
DOI : 10.1016/j.bbalip.2013.02.010
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742583/pdf

Y. Cao, Angiogenesis modulates adipogenesis and obesity. The Journal of clinical investigation, pp.2362-2370, 2007.
DOI : 10.1172/jci32239
URL : http://www.jci.org/articles/view/32239/files/pdf